Journal
JOURNAL OF DRUG TARGETING
Volume 14, Issue 9, Pages 652-661Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10611860600916636
Keywords
Parkinson's disease; L-Dopa; L-Dopa prodrugs; liposomes; microdialysis
Categories
Ask authors/readers for more resources
The maleic and fumaric diamides preparation of (O,O-diacetyl)-L-Dopa-methylester [(+)-4, (+)-5] are reported; they were synthesized in order to attenuate marked fluctuations of L-DOPA (LD) plasma levels and to overcome the problem of low bioavailability of LD. The new compounds were characterized evaluating solubility, chemical stability, apparent partition coefficient (log P) and comparing neostriatum dopamine (DA) levels in freely moving rats after i.p. administration of prodrugs [(+)-4, (+)-5] with prodrugs in liposomal formulations [(+)-4 Lip, (+)-5 Lip]. All the new compounds showed chemical stability in aqueous buffer solutions (pH 1.3 and 7.4). A relatively slow release of LD in human plasma was observed. Among the studied products, prodrug was able to induce sustained delivery of DA in rat striatal dialysate with respect to equimolar i.p admistration of LD. Furthermore, neostriatum DA concentration after administration of the synthesized prodrugs vs. prodrugs in liposomal formulations was compared (+)-4 Lip, (+)-5 Lip). The results suggest that cis dimeric prodrug (+)-4 and (+)-4 Lip can improve the release of DA in rat brain and demonstrate the potential of these formulations for controlled delivery of antiparkinson agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available